Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seliciclib - Cyclacel Pharmaceuticals

Drug Profile

Seliciclib - Cyclacel Pharmaceuticals

Alternative Names: CYC 202; R-roscovitine; Seliciclib

Latest Information Update: 23 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Developer Cedars-Sinai Health System; Cyclacel Pharmaceuticals; University Hospital, Brest; University of Newcastle upon Tyne
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cell cycle protein inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; MCL1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cushing syndrome; Cystic fibrosis; Nasopharyngeal cancer; Non-small cell lung cancer; Pituitary ACTH hypersecretion; Rheumatoid arthritis
  • No development reported Breast cancer; Solid tumours
  • Discontinued Glomerulonephritis; Haematological malignancies

Most Recent Events

  • 28 Dec 2020 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in USA (PO, Capsule)
  • 03 Jun 2020 Interim adverse events data from a phase Ib Trafic trial in rheumatoid arthritis presented at the 21st Annual Congress of the European League Against Rheumatism (EULAR-2020)
  • 03 Jun 2020 UK Medical Research Council and Cyclacel completes enrolment in the phase Ib Trafic trial for rheumatoid arthritis in United Kingdom (EudraCT2014-001339-35) (ISRCTN36667085)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top